Terms ending in 2039
Every in-force patent on Tesaro, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,730,725 | Niraparib Formulations In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 11,926,665 | Methods of Treating Cancer with ANTI-TIM-3 Antibodies In force · Medium confidence | Tesaro, Inc. | In force | Medium confidence | |
| US 11,661,453 | Combination Therapies for Treating Cancer with Niraparib and PD-1 Inhibitors In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 11,801,240 | Combination Therapies and Uses Thereof In force · High confidence | Tesaro, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.